See more : Hunan Xiangjia Animal Husbandry Co.,Ltd (002982.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Arcellx, Inc. (ACLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcellx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Topps Tiles Plc (TPTJF) Income Statement Analysis – Financial Results
- PT Mahaka Media Tbk (ABBA.JK) Income Statement Analysis – Financial Results
- Iridium Communications Inc. (0JDO.L) Income Statement Analysis – Financial Results
- Madison Ave Media, Inc. (KHZM) Income Statement Analysis – Financial Results
- GENOMIC VALLEY BIOTECH LIMITED (GVBL.BO) Income Statement Analysis – Financial Results
Arcellx, Inc. (ACLX)
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 110.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.22M | 1.04M | 629.00K | 326.00K | 0.00 |
| Gross Profit | 110.32M | -2.22M | -1.04M | -629.00K | -326.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.85M | 149.56M | 46.88M | 25.06M | 15.77M | 6.11M |
| General & Administrative | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Other Expenses | 0.00 | 0.00 | 49.00K | 1.00K | 2.00K | 0.00 |
| Operating Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Cost & Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Interest Income | 23.70M | 4.30M | 300.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 3.84M | 1.72M | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.04M | 2.22M | 1.04M | 629.00K | 326.00K | 93.00K |
| EBITDA | -64.15M | -184.74M | -63.93M | -31.47M | -17.65M | -8.22M |
| EBITDA Ratio | -58.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.88M | -191.26M | -65.02M | -32.10M | -17.97M | -8.31M |
| Operating Income Ratio | -81.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.85M | 2.58M | 49.00K | 1.00K | 2.00K | 999.00 |
| Income Before Tax | -70.03M | -188.68M | -64.97M | -32.10M | -17.97M | -8.31M |
| Income Before Tax Ratio | -63.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 663.00K | -2.58M | -1.04M | 422.70K | 154.14K | 0.00 |
| Net Income | -70.69M | -186.10M | -63.93M | -32.10M | -17.97M | -8.31M |
| Net Income Ratio | -64.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| EPS Diluted | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| Weighted Avg Shares Out | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
| Weighted Avg Shares Out (Dil) | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
The 3 Biotech Stocks That Could Make Your February Unforgettable
Source: https://incomestatements.info
Category: Stock Reports